Machado TR, Leite IS, Inada NM, Li MS, Da Silva JS, Andres J, Beltrn-Mir H, Cordoncillo E, Longo E (2019) Designing biocompatible and multicolor fluorescent hydroxyapatite nanoparticles for cell-imaging applications
During the dose-escalation phase of STEP-1, weight loss at the 0.25 mg and 0.5 mg levels was minimal, generally in the range of 2 to 4%
(2021) noted that A
Symptoms of low calcium include numbness or tingling in fingers and toes, muscle aches , cramps, and in severe cases, confusion or memory problems
56 Small molecule targeted therapy (BRAF and MEK inhibitors) and immune checkpoint inhibitors (CTLA4 and PD1) have shown promising clinical outcomes